The genome of IMiD-refractory myeloma
In this issue of Blood, Ansari-Pour et alpresent findings from their analysis on the largest whole-genome sequencing data set of relapsed and refractory multiple myeloma (rrMM), which comprised 418 tumor samples from 386 patients. The data were retrieved from 6 clinical trials that included patients refractory to lenalidomide and/or pomalidomide, which are 2 immunomodulatory imide drugs (IMiDs) that are commonly used therapeutics for newly diagnosed and relapsed patients with multiple myeloma (MM), respectively.